Dear OncoLink "Ask The Experts,"
My brother in Taiwan has stage IV colon cancer. He is currently undergoing radiation on his spine, 5 days/week. He is also receiving chemotherapy. He wants me to ask if 7 days/week of radiation treatment works better? He is scared that cancer will spread faster by not treating everyday. Thank you very much for your time.
Neha Vapiwala , MD, Radiation Oncologist at the Abramson Cancer Center of the University of Pennsylvania, responds:
Radiation therapy damages both the normal cells and the tumor cells that are located within the radiation field. These cells can heal between radiation treatments. While it is undesirable to allow tumor cells time to heal, it is very necessary to allow some time for normal tissues to repair radiation damage. Studies have taken tissue from various human organs (skin, gut, lung, liver, etc.) and exposed them to radiation to analyze the effects of radiation. These studies have taught us that a regimen of once-daily treatments over a shorter time period (eg: 7 days a week for 4 weeks) can be very damaging to certain normal cells, especially ones that divide rapidly like the skin and lining of the gut. It is also known that extending the overall treatment time, by only treating 5 days a week for 5 and a half weeks, for example, spares these tissues and limits normal tissue toxicity.
Ultimately, in order to treat your tumor you have to deliver all of the intended radiation dose. The total dose is divided into a number of smaller daily doses. In order to deliver all of the necessary daily doses, it is crucial to prevent dose-limiting toxicity (ie: if the skin is too damaged, you can't continue to treat the patient, and have to interrupt the treatment course, which is very bad from a treatment standpoint).
A way to prevent such severe toxicity is to NOT treat continuously every single day, but rather to allow 2 days a week for healing.
Historically, because of U.S. society's convention of weekends as "non-working days", those 2 days for healing were designated to be Saturday and Sunday.
Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.
Jan 14, 2013
Mar 5, 2010
Jul 9, 2010